Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. by Pawlyn, C et al.
OPEN
ORIGINAL ARTICLE
Overexpression of EZH2 in multiple myeloma is associated
with poor prognosis and dysregulation of cell cycle control
C Pawlyn1,2, MD Bright1, AF Buros3, CK Stein3, Z Walters1, LI Aronson1, F Mirabella1, JR Jones1,2, MF Kaiser1,2, BA Walker3, GH Jackson4,
PA Clarke1, PL Bergsagel5, P Workman1, M Chesi5, GJ Morgan1,3 and FE Davies1,3
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation.
Outcomes for myeloma patients have improved over the past few decades except for molecularly deﬁned high-risk patients who
continue to do badly. Novel therapeutic approaches are, therefore, required. A growing number of epigenetic inhibitors are now
available including EZH2 inhibitors that are in early-stage clinical trials for treatment of haematological and other cancers with EZH2
mutations or in which overexpression has been correlated with poor outcomes. For the ﬁrst time, we have identiﬁed and validated
a robust and independent deleterious effect of high EZH2 expression on outcomes in myeloma patients. Using two chemically
distinct small-molecule inhibitors, we demonstrate a reduction in myeloma cell proliferation with EZH2 inhibition, which leads to
cell cycle arrest followed by apoptosis. This is mediated via upregulation of cyclin-dependent kinase inhibitors associated with
removal of the inhibitory H3K27me3 mark at their gene loci. Our results suggest that EZH2 inhibition may be a potential therapeutic
strategy for the treatment of myeloma and should be investigated in clinical studies.
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KEY POINTS
1. High EZH2 mRNA expression in myeloma patients at diagnosis
is associated with poor outcomes and high-risk clinical features.
2. Speciﬁc targeting of EZH2 with well-characterised small-
molecule inhibitors in vitro leads to upregulation of cell cycle
control genes leading to cell cycle arrest and apoptosis.
INTRODUCTION
Myeloma is a malignancy of plasma cells that accumulate in the
bone marrow (BM), suppress normal haematopoiesis, lyse bone
and secrete monoclonal immunoglobulin into the blood. Out-
comes for many myeloma patients have improved over the past
two decades with the introduction of proteasome inhibitors,
immunomodulatory drugs and, more recently, monoclonal anti-
bodies. However, high-risk disease, characterised by ⩾ 1 adverse
cytogenetic features (t(4;14), t(14;16), t(14;20), 1q+, 17p− )1,2 or
distinct gene expression proﬁles (for example, UAMS GEP70
score)3 remains therapeutically intractable, with little evidence
that currently available therapies have improved patient
outcomes.4 New treatment strategies are therefore urgently
required.
Myeloma is molecularly heterogeneous with a number of clear
molecular subgroups deﬁned at the DNA or gene expression level.
Epigenetic modiﬁcations also have an important role in myeloma
pathogenesis:5 one of the primary translocation events, which
occurs in a high proportion of GEP70 high-risk patients, t(4;14),
leads to upregulation of the histone 3 lysine 36 (H3K36)
methyltransferase MMSET.6–9 In addition, changes in DNA
methylation patterns have been identiﬁed between subgroups
and with advancing stages of disease.10
A unifying characteristic across subgroups is dysregulation of
the G1/S cell cycle checkpoint mediated via overexpression of a
D group cyclin.11 The cyclin Ds, in complex with cyclin-dependent
kinase 4/6 (CDK4/6), phosphorylate Rb protein, initiating DNA
transcription and driving cell proliferation. Higher rates of
proliferation are associated with advanced disease stages and
with high-risk compared with low-risk disease.12,13 Targeting
proliferation via cell cycle control proteins is, therefore, an
attractive therapeutic target for such disease segments. Targeting
the epigenetic events that impact on this cell cycle checkpoint
could provide a novel therapeutic strategy.
EZH2 is a histone methyltransferase acting primarily at H3K27
where it catalyses the conversion to a tri-methylated mark
(H3K27me3), a modiﬁcation associated with the repression of
gene expression.14,15 The methyltransferase activity of EZH2 is
speciﬁcally mediated via the SET domain of the protein.16 It is a
member of the polycomb repressive complex (PRC2), which is
comprised of EZH2 with EED, SUZ12 and RbAp48 and accessory
proteins, such as JARID2 and ASXL1.14 The maintenance of the
structure of this complex is important for the function of EZH2.
The histone demethylase UTX/KDM6A, which is frequently lost in
myeloma cell lines and in some patient samples,17 removes the
H3K27me2/3 marks, counteracting the activity of EZH2.18
EZH2 has an important role in normal B-cell development, with
the expression and H3K27me3 levels inﬂuencing differentiation
decisions.19,20 EZH2 expression is high in germinal centre B cells
resulting in the silencing of cell cycle checkpoints and allowing
B cell expansion with a subsequent reduction in EZH2, allowing
cells to differentiate into plasma cells. Transformation of germinal
centre cells by EZH2-activating mutations, occurring in the SET
domain, has been shown to drive up to a quarter diffuse large
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B-cell and 10% of follicular lymphomas, circumventing normal
cellular differentiation.21 High expression of EZH2 has also been
linked to adverse outcome and aggressive tumour biology in
numerous solid tumours and haematological malignancies,
including breast, lung, bladder and chronic lymphocytic
lymphoma.22–26 Even in diffuse large B-cell lymphoma, high
EZH2 expression leads to high levels of H3K27me3, independent
of the presence of a mutation and is associated with high-grade
features.27 Inactivating mutations in the H3K27 demethylase
KDM6A (also potentially leading to pathologically high
H3K27me3) have also been identiﬁed and these, along with the
presence of ARID1A mutations, have been suggested to sensitise
cells to EZH2 inhibition.28,29 Based on targeting the oncogeneic
activity of EZH2, a number of speciﬁc small-molecule inhibitors
have been developed with three compounds in early-phase
clinical studies (http://www.clinicaltrials.gov).
We have previously analysed DNA from almost 500 cases of
newly diagnosed myeloma patients and their paired germline
controls.30,31 No patients had mutations in EZH2, but 3% of
patients had potentially inactivating mutations or deletions in its
partner demethylase KDM6A, with evidence of a negative effect on
patient outcomes. Previous studies have shown an increase in
EZH2 expression as disease progresses from monoclonal gammo-
pathy of undetermined signiﬁcance (MGUS) through smouldering
myeloma to myeloma and that genes underexpressed in multiple
myeloma (MM) are associated with H3K27me3 targets in
embryonic stem cells.16,32 In addition, it has been suggested that
MMSET overexpression in myeloma may drive genome-wide
redistribution of EZH2 and H3K27me3 marks.33 Recent studies
have indicated that myeloma cells may respond to EZH2 inhibition
but with variation across cell lines and no clear biomarker
predictive of response identiﬁed.34,35
Using large data sets totalling almost 1500 patients in several
phase III clinical trials using different therapeutic strategies, we, for
the ﬁrst time, identify and validate a robust and independent
deleterious effect of high EZH2 gene expression on outcomes in
myeloma patients. Using two chemically distinct, speciﬁc, small-
molecule inhibitors in myeloma cell lines and primary patient cells,
we demonstrate EZH2 to be a therapeutic target in myeloma,
including cases with high-risk features. We ﬁnd that inhibition of
EZH2 in myeloma induces cell cycle arrest followed by apoptosis.
Analysis of mRNA and protein expression changes following
inhibition suggests that this is mediated via upregulation of cell
cycle control genes, the CDK inhibitors CDKN1A/p21 and CDKN2B/
p15, which we demonstrate to be regulated by H3K27me3. These
gene expression changes only occur at dose and time points that
inhibit cellular proliferation, suggesting that they could be used as
a biomarker of efﬁcacy. Our study demonstrates that EZH2
inhibition may be an effective therapeutic strategy for myeloma
patients, potentially even for those with high-risk disease for
whom current approaches are ineffective.
MATERIALS AND METHODS
Expression and survival analysis
Gene expression proﬁling (GEP) was performed for patients enrolled in the
MRC Myeloma IX trial (MyIX, n= 259, GSE21349) and Total Therapy trials
(UAMS-TT, n=1230, GSE2658, GSE38627) as previously described.1,13,36–42
These trials used very different induction treatment regimens
(Supplementary Methods). Expression of EZH2 was measured using the
203358_s_at probeset, conﬁrmed to have good coverage, sensitivity and
speciﬁcity for EZH2 (UCSC genome browser, www.genome.ucsc.edu and
GeneAnnot from Genecard, ww.genecards.weizmann.ac.il/geneannot). The
optimal cut point was deﬁned for EZH2 in each data set, and Kaplan–Meier
curves were drawn to compare high expressers to low expressers. Survival
was compared using the Logrank statistic. Univariate and multivariate
analysis with Cox proportional hazards regression was performed within
each data set. All covariates considered in the univariate model were
included in the multivariate model. Analysis was carried out using R 3.2.3,43
SAS 9.4 (SAS Institute, Cary, NC, USA) and SPSS 22 (IBM, New York, NY,
USA). A probability value of o0.05 was considered statistically signiﬁcant.
Expression was compared across the UAMS subgroups13 and between
GEP70 low- and high-risk groups3 in the Total Therapy trials. Correlation
between EZH2 expression and both the GEP70 absolute score and
proliferation index12,13 was also calculated.
Cell lines and reagents
MM cell lines, KMS11, JIM3, MM1.S, LP1, KMS12BM, RPMI8226, KMM1 and
U266, were grown in RPMI1640 medium containing GlutaMax (Gibco,
Thermo Fisher Scientiﬁc, Waltham, MA, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco, Thermo Fisher Scientiﬁc). The HS5
stromal cell line was grown in Dulbecco’s modiﬁed Eagle’s medium (Gibco,
Thermo Fisher Scientiﬁc) supplemented with 10% heat-inactivated foetal
bovine serum. This cell line was transfected with a green ﬂuorescent
protein (GFP) short hairpin RNA viral vector to produce the stable HS5-GFP
cell line. GFP expression was conﬁrmed to be 495% prior to each
experiment. Cell line identity was conﬁrmed using single tandem repeat
analysis and cells tested negative for mycoplasma (PCR Mycoplasma Test
Kit, Promokine, Heidelburg, Germany). Cell cultures were kept at 37 °C in a
humidiﬁed gas chamber with 95 air and 5% carbon dioxide.
UNC1999 and UNC2400 were a kind gift from The Structural Genomics
Consortium, Toronto, ON, Canada. EPZ005687 was synthesised in house.44
Compounds were dissolved in dimethyl sulphoxide (DMSO) to a 50 mM
stock solution and stored in aliquots at − 20 °C.
Primary patient samples
BM aspirate samples were obtained from relapsing myeloma patients with
consent after approval by The Royal Marsden review board. The white cell
layer was separated by density gradient centrifugation using Ficoll-Paque
Premium (GE Healthcare UK Ltd, Little Chalfont, Buckinghamshire, UK).
CD138+ plasma cells were selected using antibodies conjugated to
magnetic beads (Miltenyi-Biotech, Bergish Gladbach, Germany). Purity was
conﬁrmed to be 490% by microscopy following cytospin and modiﬁed
Wrights staining (Haematek, Siemens Healthcare, Erlangan, Germany).
Patient sample molecular features were characterised using quantitative
reverse transcriptase-PCR (qRT-PCR) and multiplex ligation-dependent
probe ampliﬁcation as previously described.45,46 Peripheral blood mono-
nuclear cells were separated from whole blood using Ficoll-Paque
Premium (GE Healthcare UK Ltd, Little Chalfont, Buckinghamshire, UK) by
density gradient centrifugation.
Cell viability, cell cycle and apoptosis assays
Inhibition of proliferation in cell lines was measured using the in vitro
WST-1 colorimetric assay (Roche, Penzberg, Germany). Propidium iodide
(PI) staining followed by ﬂow cytometry (LSRII ﬂow cytometer, Beckton
Dickinson, Oxford, UK) was used to analyse the cell cycle. Annexin V/PI
staining was used to look for evidence of apoptosis with the proportion of
Annexin V plus Annexin V- and PI-positive cells (compared with DMSO
control) calculated. Flow cytometric data was analysed using the BD
FACSDiva software (Beckton Dickinson, Franklin Lakes, NJ, USA) and/or
FlowJo (Ashland, OR, USA). The Caspase-Glo 3/7 luminescent assay
(Promega, Madison, WI, USA ) was used to compare caspase activity after
cell number was normalised.
Co-culture of BM stroma and CD138+ patient plasma cells
HS5-GFP and CD138+ cells were co-cultured in a 1:5 ratio and incubated
for 72 h with the indicated compound/control. Flow cytometric analysis
was performed as above but with Annexin V and 4’,6-diamidino-2-
phenylindole (DAPI) instead of PI (to avoid crossover with GFP signal) and
by gating on only GFP-negative cells to assess Annexin V/DAPI staining in
the myeloma cells. Viability was determined by the proportion of Annexin
V- and DAPI-negative cells (compared with DMSO control).
Chromatin immunoprecipitation–PCR (ChIP-PCR)
ChIP-PCR was performed using the ChIP-IT Express Enzymatic Kit (Active
Motif, Carlsbad, CA, USA) with optimisations/modiﬁcations as described in
Supplementary Methods.
Primers were designed using Primer Express (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) at the transcriptional start site (TSS) and the promoter
(PROM) region of each gene of interest at areas that appeared marked with
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regulatory/PROM elements using tracks from ENCODE on UCSC genome
browser. Additional primers were designed to regions approximately 5 Kb
upstream of the TSS and not marked by ENCODE tracks. Positive and
negative control primer sets were also run (Active Motif). Percentage of
input calculations for each sample were made using the standard curve
and the comparative CT method. All samples were run in duplicate and the
mean taken for each experiment. ChIP-PCR was repeated with a second
complete biological replicate.
Methods for western blotting and qRT-PCR are given in Supplementary
Methods.
RESULTS
High EZH2 mRNA expression is associated with worse outcomes
for patients and molecular features of high-risk disease
Given the evidence associating EZH2 expression and oncogenesis
in other cancers, we investigated its effect in myeloma patients.
Using a much larger data set than previously reported (UAMS
n= 1621), we conﬁrmed an increase in the expression of
EZH2 mRNA as myeloma progresses with the highest expre-
ssion in symptomatic myeloma (MGUS vs MM adjusted
Po0.00001, smouldering multiple myeloma (SMM) vs MM
adjusted Po0.00001, MGUS vs SMM not signiﬁcant; Figure 1a).
We therefore went on to assess the effect of EZH2 expression on
clinical outcomes. In two large independent data sets of phase III
clinical trial patients, MyIX n= 259 and UAMS-TT n= 1230, we
found that high expression of EZH2 was associated with shortened
progression-free and overall survival (Figure 1b and
Supplementary Figure S1), with a reduction in median overall
survival from 3.76 to 2.37 years (Logrank P= 0.00067) and from
12.1 to 4.61 years (Logrank P= 4.4e-20), respectively. In these
studies, patients received very different treatment regimens,
suggesting that this effect is independent of therapy and persists
even with immunomodulatory drug/proteasome inhibitor combi-
nation treatment used in the Total Therapy studies. In both data
sets, the impact of EZH2 expression remained signiﬁcant on
multivariate analysis (Supplementary Tables S1 and S2), demon-
strating its effect is independent of other factors known to affect
survival in myeloma patients including International Staging
System, GEP70 risk and adverse cytogenetics.
EZH2 expression was signiﬁcantly higher in the UAMS
molecularly deﬁned PR subgroup,13 which is characterised by
the overexpression of cancer-testis antigens, cell cycle and
proliferation-related genes (Figure 1c), and was signiﬁcantly
higher in GEP70 high-risk patients (Figure 1d). There was also a
Figure 1. High expression of EZH2 is associated with poor patient outcomes and features of high-risk and proliferative disease. (a) Box and
whisker plot showing EZH2 expression in UAMS data set (MGUS n= 114, SMM n= 163, MM n= 1344) Log 2 expression values. One-way analysis
of variance (F ratio 84.53, Po2e-16) followed by Tukey’s multiple comparison test demonstrated signiﬁcant difference between MGUS and
MM (adj. P⩽ 0.00001) and between SMM and MM (adj. P⩽ 0.00001). (b) Kaplan–Meier curves showing OS (i) in the MyIX data set comparing
high EZH2 mRNA (48.24, log 2 expression value, n= 31) to all others (n= 228). Median OS 2.37 years (95% CI (1.12, 3.64)) vs 3.76 (95% CI (3.27,
4.28)). Logrank P= 0.00067 and (ii) in the UAMS-TT data set comparing high EZH2 (49.32, log 2 expression value n= 254) to all others (n= 967).
Median OS 4.61 years (95% CI (3.77, 6.06)) vs 12.1 (95% CI (10.8, 13.5)). Logrank P= 4.4e-20. (c) Box and whisker plot showing the EZH2
expression across the UAMS molecular subgroups. Log 2 expression values. PR mean expression 9.56 vs all other 8.48, one-sided Welch’s t-test
P= 5.953e-42. (d) Box and whisker plots showing the EZH2 expression across UAMS GEP70 high- vs low-risk patients. High-risk GEP70 had a
higher mean expression of EZH2 (9.61 vs 8.46, one-sided Welch’s t-test P-value= 1.993e-40). GEP70 scores also signiﬁcantly correlated with
EZH2 expression (Pearson correlation of 0.611). (e) High-density scatter plot demonstrating the correlation between the EZH2 expression and
the gene expression-deﬁned proliferation index. R= 0.79, Po0.0001.
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marked correlation with a gene expression-deﬁned proliferation
index (Figure 1e, R= 0.79, Po0.0001).12 This suggests EZH2
expression could contribute to the high-risk phenotype. We
therefore sought to investigate the effect of EZH2 inhibition in
myeloma in vitro.
In order to examine the effect of EZH2 inhibition with EZH2
in situ in the PRC complex, we used the well-characterised small-
molecule inhibitors available, rather than taking a knockdown
approach that would disrupt the whole complex. In this study, we
utilised two chemically distinct EZH2 inhibitors, EPZ00568744 and
EZH2 as a therapeutic target in myeloma
C Pawlyn et al
4
Blood Cancer Journal
UNC1999,47,48 along with a paired inactive analogue, UNC2400, in
order to robustly demonstrate the effects to be EZH2 speciﬁc.
EZH2 inhibition reduces myeloma cell viability in a time- and
concentration-dependent manner
We ﬁrst investigated the effect of EZH2 inhibition with EPZ005687
over 72 h using the colourimetric WST-1 viability assay in a panel
of eight cell lines all of which were conﬁrmed to express EZH2
by immunoblotting (Supplementary Figure S2A). EPZ005687
reduced viability in all myeloma cell lines in a time- and
concentration-dependent manner even in those with high-risk
features, such as t(4;14)/t(14;16), TP53 mut/del or both. (Figure 2a,
Supplementary Figure S2B and Supplementary Table S3). The
GI50s were similar across cell lines (one-way analysis of variance
P40.05) at 72 h (8–12 uM).
In order to assess the effect of EZH2 inhibition in a more
physiological setting, we co-cultured primary patient samples with
BM stromal cells to simulate the protective BM microenvironment.
We assessed viability using ﬂow cytometry after 72 h of co-culture in
the presence of EPZ005687 and found similar responses in patient
cells to those seen in cell lines. (Figure 2b and Supplementary
Figure S2C). These responses were seen despite heavy pretreatment
of patients (median two prior lines of therapy, Table 1), and several
samples carried at least one high-risk molecular feature, such as
17p− , 1q+ or t(4;14). We demonstrated a smaller reduction in
viability at similar concentrations of EPZ005687 in normal donor
peripheral blood mononuclear cells and BM stromal cells cultured
alone (Supplementary Figures S2E and F). This suggests that a
therapeutic index exists for the response to EZH2 inhibition between
myeloma and non-malignant cells.
Given the previously published work looking at EZH2 inhibition
in lymphoma over longer time periods, we extended our viability
assays to 6 days using EPZ005687 at lower concentrations.44,49 We
demonstrated a reduction in viability following EZH2 inhibition, at
this time point, in most cell lines using the WST-1 viability assay
(Figure 2c) with no evidence of response in only 2/8 cell lines
(JIM3 and U266). Our studies did not reveal any of the previously
reported dependencies of EZH2 inhibition on the presence of
high levels of MMSET,33 a KDM6A mutation or deletion26 or an
ARID1A mutation.29 Neither was response related to the cell
doubling time or level of baseline EZH2 or H3K27me3 expression
(Supplementary Figures S2A and D, Supplementary Table S4).
Next, in order to conﬁrm that our results were due to speciﬁc
inhibition of EZH2 we repeated our viability experiments using the
chemically distinct inhibitor UNC1999 and its negative control
compound UNC2400. At both 3 and 6 days, we demonstrated
inhibition of proliferation with UNC1999 at slightly lower concen-
trations than EPZ005687 (Supplementary Figures S3A and C). A lack
of response with the negative control compound UNC2400 and the
same pattern of response across cell lines, with JIM3 cells not
responding at 6 days, conﬁrmed that this effect was most likely
due to speciﬁc inhibition of EZH2 methyltransferase activity
(Supplementary Figures S3B–D).
We selected the KMS11 and KMM1 cell lines to study in further
detail as representative responsive cell lines at 6 days, one from
the t(4;14) subgroup and one with none of the features previously
suggested to confer sensitivity to EZH2 inhibition.28,29,33
EZH2 inhibition mediates its antiproliferative effect by inducing
cell cycle arrest followed by apoptosis
We next sought to identify the mechanism by which EZH2
inhibition exerts its antiproliferative effect. Using cell ﬁxation
followed by PI staining, we demonstrated cell cycle arrest at the
G1 phase following 3 days of EZH2 inhibition (Figure 2d). At
6 days, we found evidence of apoptosis by ﬂow cytometry with an
increase in Annexin and Annexin V/PI staining with increasing
concentrations of EPZ005687 (Figure 2e). We conﬁrmed this
ﬁnding by demonstrating an increase in cells in oG1 on cell cycle
analysis (Supplementary Figure S4A), an increase in caspase
activity using the luminescent CaspaseGlo 3/7 assay
(Supplementary Figure S4B) and poly ADP-ribose polymerase
cleavage by immunoblotting (Supplementary Figure S4C).
EZH2 inhibition upregulates cell cycle control genes to exert its
antiproliferative effect by removing the inhibitory H3K27me3 mark
Halting proliferative drive, allowing cells to exit the cell cycle, is
necessary for cell differentiation and/or apoptosis. In addition to
our ﬁnding of cell cycle arrest following EZH2 inhibition,
Affymetrix gene expression arrays (U133plus2.0) in KMS11 and
KMM1 cell lines demonstrated upregulation of genes relating to
cell cycle control following treatment with EPZ005687
(Supplementary Tables S5 and S6). In the KMS11 cell line, one of
the most signiﬁcantly upregulated genes was CDKN2B, a CDK
inhibitor known to inhibit cyclin D/CDK complexes in G1.50 In
Figure 2. Speciﬁc EZH2 inhibition is efﬁcacious in vitro in both myeloma cell line and primary patient samples, even those with high-risk
features. EZH2 inhibition induces cell cycle arrest followed by apoptosis. (a) Cell viability determined using the WST1 assay (normalised to
DMSO control) in a panel of eight myeloma cell lines incubated with increasing concentrations of EZH2 inhibitor (EPZ005687) for 72 h. The
GI50 for each cell line (calculated using the Graphpad Prism software) is shown. There was no statistically signiﬁcant difference between the
GI50s for each cell line (one-way analysis of variance (ANOVA) P40.05). Graph shows mean and s.e.m. of at least three independent biological
replicates. (b) CD138 selected plasma cells from six patients’ BM aspirate samples were co-cultured with the BM stromal cell line HS5 (GFP
tagged) for 72 h in the presence of the indicated concentration of EPZ005687 or vehicle control (DMSO). Cells were then stained with Annexin
V and DAPI prior to ﬂow cytometric analysis. Results show the percentage of cell viability (of DMSO) measured as the percentage of cells that
were Annexin V and PI-negative within the GFP-negative fraction. Raw data and mean value (horizontal line) are shown. One sample t-tests
were performed to look for a signiﬁcant reduction in viability at each concentration compared with 100%. Those with P-valueso0.05 are
indicated by an asterisk (*). (c) Cell viability determined using the WST1 assay (normalised to DMSO control) in a panel of eight myeloma cell
lines incubated with increasing concentrations of EZH2 inhibitor (EPZ005687) for 6 days. Graph shows mean and s.e.m. of at least three
independent replicates in each cell line. The cell line features of factors previously demonstrated to be relevant to EZH2 inhibition in myeloma
and TP53 status are shown in the table below with further details in Supplementary Table S3. Of note, no cell lines used had EZH2 mutations
(details from Broad CCLE, MMRF Myeloma Cell Line Characterization Data repository and van Haaften et al.17). HD=homozygous deletion,
hom=homozygous mutation, het=heterozygous mutation. One sample t-tests were performed to look for a signiﬁcant reduction in viability
at 4 μM compared with 100%. Those with P-valueso0.05 are indicated by an asterisk (*). (d) Cell cycle analysis with propidium iodide staining
was performed following EZH2 inhibition with EPZ005687 for 3 days in KMS11 and KMM1 cell lines. The cells in each phase of the cell cycle are
shown as a percentage of all cells in cycle. Results shown mean and s.e.m. of three independent replicate experiments. The mean percentage
of cells in G1 was compared across conditions using a one-way ANOVA followed by multiple comparisons to DMSO control. There was a
signiﬁcant increase (adj. Po0.05) in G1% indicated by an asterisk (*). (e) Apoptosis was assessed after 6 days of incubation with increasing
concentrations of EPZ005687 and compared with DMSO control by Annexin V/PI staining in the panel of eight cell lines. One sample t-tests
were performed to look for a signiﬁcant increase at each concentration compared with 1. Statistical signiﬁcance (Po0.05) is indicated by an
asterisk (*).
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KMM1, IFIT3 had increased expression following EZH2i. IFIT3 has
previously been demonstrated to upregulate CDKN1A via down-
regulation of MYC and directly upregulate CDKN1B.51 We validated
these ﬁndings by incubating cells over 3 and 6 days with
EPZ005687 or UNC1999 and then analysing gene expression
changes using qRT-PCR. In KMS11, there was evidence of
upregulation of both CDKN2B and the IFIT3/MYC/CDKN1A pathway.
In KMM1, only the IFIT3/MYC/CDKN1A pathway appeared to be
upregulated (Figure 3a). Using the negative control compound
UNC2400, we conﬁrmed that these ﬁndings were EZH2 speciﬁc
(Supplementary Figure S5). mRNA changes were also demon-
strated at the protein level by immunoblotting (p15 for CDKN2B
and p21 for CDKN1A; Figure 3b).
To further determine whether the gene expression changes were
mediated by a change in the H3K27me3 status of the gene, we
performed ChIP-PCR using a validated antibody for H3K27me3 (Active
Motif, no. 61017) and isotype control. Following incubation of
KMS11 cells with EPZ005687 over 6 days, we identiﬁed changes in
H3K27me3 in the PROM and TSS regions of CDKN2B, IFIT3 and CDKN1A
(Figure 3c). The most speciﬁc changes, however, occurred at the
CDKN1A PROM/TSS, which were more heavily marked with H3K27me3
at baseline compared with a region approximately 5 Kb upstream.
Pulldown in the isotype control-incubated samples was negligible.
These results suggest that CDKN1A expression might be
controlled by changes in H3K27me3 and so we explored the effect
of CDKN1A mRNA expression in our patient data sets. We found the
expression of EZH2 and CDKN1A to be inversely correlated
(R=−0.170, Po0.0001, Supplementary Figure S6), supporting the
hypothesis that CDKN1A expression is suppressed by increased
H3K27me3 as a result of high expression of EZH2. In addition, low
expression of CDKN1A was associated with a signiﬁcantly shorter
progression-free and overall survival (Figure 3d).
Changes in the expression of cell cycle control genes correlate
with the antiproliferative effect of EZH2 inhibition
In order to identify a potential biomarker of response, we next
looked across our original panel of eight myeloma cell lines
incubating cells over 6 days, a time point at which we had seen
the most variability in response to EZH2 inhibition. Using whole-
cell lysates, we ﬁrst examined global changes in EZH2 and H3K27
methyl marks (Figure 4a and Supplementary Figure S7A). No
consistent change in EZH2 expression was seen following
inhibition; however, a marked reduction in H3K27me3 occurred
across all cell lines. Changes in H3K27me2 mirrored H3K27me3,
whereas in contrast H3K27me1 does not appear to be altered
(Supplementary Figure S7B), supporting previous ﬁndings in other
tumour types.52 These studies conﬁrmed the modulation of the
expected target activity of the inhibitor across cell lines but did
not differentiate between responses—suggesting that global
changes in methyl marks cannot be used as a predictive
biomarker. Instead differential response must be due to varied
effects of H3K27me3 alteration dependent on different transcrip-
tional networks determined by the cellular context.
We, therefore, examined the transcriptional proﬁles across all eight
cell lines in response to EZH2 inhibition at 6 days using qRT-PCR for
the genes examined above plus other genes involved in cell cycle
control (Figure 4b and Supplementary Figure S8). We identiﬁed a
consistent increase in the expression of the CDK inhibitor CDKN1A in
responding cell lines. This increase was independent of the TP53
status of the cell line but was not consistently associated with an
increase in IFIT3 and decrease in MYC expression that had been seen
in the KMM1 and KMS11 cell lines—indicating involvement of the
IFIT3/MYC/CDKN1A pathway. This suggests that CDKN1A might be
directly regulated by H3K27me3 changes (as is suggested by our
ChIP-PCR results in KMS11) as well as indirectly via IFIT3/MYC, with
variation between cell lines. In some cell lines (KMS11, MM1S, LP1 and
KMM1), there was also an increase in the expression of CDKN2B. There
was no evidence of a direct action of IFIT3 upregulation on CDKN1B
(another known target of IFIT351) with no pattern of increased
expression of CDKN1B correlating with IFIT3 expression in any cell line
(Supplementary Figure S8). Importantly, there was no increase in the
mRNA expression of either CDKN1A or CDKN2B in the cell lines that
did not respond at this concentration and time point (JIM3 and U266),
suggesting that changes in the expression of these genes could be a
useful biomarker of response that should be validated in vivo.
DISCUSSION
For the ﬁrst time, we have identiﬁed an association between EZH2
expression and survival in myeloma that is robust across different
data sets, persists regardless of therapy used and is independent of
other factors known to inﬂuence myeloma patient survival. This
reinforces the importance of EZH2 expression in myeloma pathogen-
esis. Our ﬁndings agree with data from solid tumours and other
haematological malignancies in which upregulation of EZH2 has been
linked to tumour aggressiveness and poor outcomes.22–24 Some
studies have suggested that EZH2might be involved in transcriptional
activation rather than repression and that this activation might drive
tumour progression. An example of this is in prostate cancer where
EZH2 acted as a co-activator for transcription factors independent of
the PRC2 complex.53 In addition, other studies have suggested that
elevated expression of EZH2 at diagnosis may be associated with a
better prognosis.54 This would not appear to be the case in myeloma,
where we have shown high EZH2 expression to be associated with
features of aggressive disease, for example, increased proliferation
rate and high GEP70 score. These observations are important when
considering the use of EZH2 inhibitors as therapeutic strategies.
In order to gain insights into the biology of EZH2 without
disruption of the PRC2 complex in myeloma, we took advantage
Table 1. Clinical and molecular features of the patients used for the analysis of EPZ005687 in primary patient CD138 selected cells
Patient number Clinical features Molecular features
Age at the time
of relapse (years)
No. of prior therapies Time from ﬁrst
diagnosis (months)





1 57 2 36 Y Y None 17p−
2 56 1 27 Y Y t(11;14) None
3 69 6 109 Y Y t(4;14) FGFR3- 1p− , 1q amp
4 50 4 33 Y Y t(4;14) FGFR3+ 1q+
5 66 2 40 Y Y None 1q+
6 85 1 46 Y N HRD 1q+, 17p−
Median 61.5 2 38
Abbreviations: HRD, hyperdiploid; IMiD, immunomodulatory drug; N, no; PI, proteasome inhibitor; Y, yes.
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of the recent discovery of potent and selective EZH2 inhibitors.
There are currently three compounds in early-stage clinical trials
across different tumour types (http://www.clinicaltrials.gov). The
inhibitors were initially developed with the aim of targeting
lymphomas with activating mutations but the phase I studies have
seen some responses in wild-type patients and so ongoing studies
continue to recruit patients with both mutant and wild-type
disease.55 In vitro, the inhibitors have demonstrated activity
against both the mutant and wild-type protein. The inhibitors
used in this present study, EPZ005687 and UNC1999, have been
well characterised in previous studies and have been shown to be
speciﬁc for EZH2 with few off-target effects.44,47,48 We were,
therefore, able to study the effect of inhibition of EZH2 activity in
myeloma more speciﬁcally than by taking a genetic knockdown
approach, which would disrupt the PRC2 complex formation as a
whole and potentially yield results that might not correlate with
pharmacological inhibition in patients.
Using this approach, we demonstrate the in vitro efﬁcacy of
EZH2 inhibition in both myeloma cell lines and in primary patient
samples despite the protective effect of a modelled BM niche.
Many of the cell lines and the patient samples had features of high
risk disease—suggesting that EZH2 inhibition is active even in this
setting. This is particularly promising given the lack of effective
therapeutic options for these patients.4 Importantly, we identify a
therapeutic index between myeloma and normal peripheral blood
cells, supporting the rationale for EZH2 inhibition as a therapeutic
strategy for myeloma patients.
We ﬁnd that mechanistically inhibition of EZH2 function ﬁrst
leads to cell cycle arrest and this is followed by apoptosis. EZH2
has been shown to have a critical role in the programming of
Figure 3. EZH2 inhibition upregulates cell cycle control genes to exert its antiproliferative effect. (a) Fold change in mRNA levels in EPZ005687-
and UNC1999-treated KMS11 and KMM1 cell lines at 3 and 6 days, compared with DMSO control at the same time point, measured by qRT-
PCR. Graphs show mean and s.e.m. for at least three independent replicate experiments. GAPDH was used as the internal control. (b) p15 and
p21 immunoblotting of lysates from KMS11 and KMM1 cell lines after 3 and 6 days’ incubation with EPZ005687. Actin was used as the loading
control. Blots shown are representative of two independent experiments. (c) ChIP with H3K27me3 antibody followed by qRT-PCR at regions
indicated in samples incubated for 6 days with DMSO control or EPZ005687 at the indicated concentrations. Pulldown of genes is shown as
the percentage of input. Active motif negative and positive controls were used (mapping to genes ACTB and MYT1, respectively). An
additional region approximately 5 kb (see supplementary Methods) upstream of each gene of interest was also assayed. Isotype control
antibody led to negligible pulldown (data not shown). (d) Kaplan–Meier curves showing OS in the UAMS-TT data set comparing patients with
low CDKN1A expression (o10.6, log 2 expression value n= 105) to all others (n= 1125). Median OS 3.56 years (95% CI (2.87, 6.17)) vs 10.9 (95%
CI (10.1, 12.4)). Logrank P= 6.1e-12.
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Figure 4. Global changes in H3K27me3 are associated with cell context-speciﬁc gene expression changes. (a) Immunoblotting of EZH2 and
H3K27me3 from whole-cell lysates following 6 days’ incubation with EPZ005687 across the panel of eight cell lines. Actin and total H3 were
used as the loading controls, respectively. (b) Fold change in mRNA levels measured by qRT-PCR in EPZ005687-treated cell lines at 6 days,
compared with DMSO control. Graphs show mean and s.e.m. for at least three independent replicate experiments. GAPDH was used as the
internal control. CDKN2B in JIM3 cells and IFIT3 in KMS12BM cells were not expressed at levels to allow reliable quantiﬁcation of any change in
the expression. Additional gene expression results are shown in Supplementary Figure S8. (c) Putative mechanism of action of EZH2 in
myeloma cell lines. The upper part of the diagram demonstrates the change in chromatin structure in the presence of active vs inhibited
EZH2, resulting in a change in the methylation status of H3K27. Where EZH2 is not inhibited, H3K27me3 is high and chromatin structure is
closed preventing gene transcription. EZH2 inhibition removes methyl marks, chromatin relaxes and genes affected by the H3K27me3 mark
are able to be transcribed. We show that CDKN1A and CDKN2B may be directly under the control of H3K27me3 or their transcription might be
altered as a downstream result of the expression of another gene being altered. The lower part of the diagram demonstrates the cyclin D/CDK
and cyclin E/CDK complexes driving cell proliferation in myeloma at the G1/S checkpoint. Upregulation of the CDK inhibitors can inhibit these
complexes preventing passage of cells from G1 to S phase as shown.
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normal B-cell development and to act as a modiﬁer deﬁning the
balance between clonal expansion and terminal differentiation, a
critical balance at this stage of lymphoid development.19 In this
setting, it is necessary for cells to come out of cell cycle in order to
complete terminal differentiation and ultimately to undergo
programmed cell death. Overexpression of EZH2 may function
to prevent this switch by driving cell cycle progression. We went
on to show that the molecular mechanism mediated via EZH2
inhibition is via either direct or indirect changes to the expression
of cell cycle control genes. Results in KMS11 cells suggest that
these effects might be due to focal alterations of H3K27me3 at the
CDKN1A TSS and PROM region, but the pattern of gene expression
changes supports the hypothesis that both direct and/or indirect
changes in gene transcription of cell cycle inhibitors due to EZH2
inhibition, depending on the cellular context, lead to the same
ﬁnal common outcome (Figure 4c). In contrast, previous studies in
myeloma, identifying other genes thought to be regulated by
EZH2, did not identify a unifying transcriptional pattern in
responding vs non-responding cell lines.34,35
p21 is a member of the cip/kip family of CDK inhibitors.56
CDKN1A/p21 and other cell cycle control genes have previously
been identiﬁed to be targets of EZH2/H3K27me3 in other cancers,
including breast, prostate, endometrial, melanoma and non-
Hodgkin’s lymphoma.26 p21 is known to be a major target for
transactivation by the tumour-suppressor gene p53 and is
required for p53-dependent G1 and G2 arrest.57,58 It has also
previously been demonstrated to act independently of p53, as a
tumour-suppressor gene in its own right,56 as is demonstrated by
our results. p21 can not only act as a direct cell cycle inhibitor but
can also supress transcription of other cell cycle control genes and
promote apoptosis.59 EZH2 inhibition has been shown to increase
p21 expression in acute myeloma leukaemia and gastric
cancer60,61 independent of p53 status and in melanoma where
EZH2 was shown to be able to overcome p53-dependent
senescence to promote the malignant phenotype.62 Our results
support these studies and thus in myeloma inhibition of EZH2
might be used to treat patients with high-risk disease.
In myeloma, repression of other CDK inhibitors has been shown
to drive tumourigenesis. CDKN2C (p18) is deleted in myeloma clones
with 1p− ,63 associated with a poor prognosis. CDKN2A (p15) and
CDKN2B (p16) have been shown to be silenced by DNA methylation
resulting in delayed cell apoptosis, poor response to chemotherapy
and a shorter overall survival.64–66 Given the link between
H3K27me3 and changes in DNA methylation,67 this supports our
results suggesting that EZH2’s role in tumourgenicity may be by
repression of CDKN1A/p21 and CDKN2B/p15 via H3K27me3 silen-
cing. This leaves unchecked the driving overexpression of cyclin D
genes found in all subtypes of myeloma, leading to uncontrolled
proliferation. Reversal of the H3K27me3 repression gives us the
opportunity to control proliferation therapeutically.
In summary, we present evidence that EZH2 is an important
therapeutic target in myeloma and suggest that clinical trials of
EZH2 inhibitors enrolling myeloma patients should be considered.
CONFLICT OF INTEREST
The Institute of Cancer Research has a commercial interest in the development of
epigenetic-modiﬁer inhibitors.
ACKNOWLEDGEMENTS
We are grateful for funding from The Wellcome Trust (CP: Wellcome Trust Clinical
Research Fellow, 102363/Z/13/Z), Cancer Research UK (FED: CRUK Senior Cancer
Fellow, C20826/A1210) and Myeloma UK as well as NHS funding to the NIHR
Biomedical Research Centre at The Royal Marsden and The Institute of Cancer
Research. We also thank Ian Titley from the FACS core facility at the ICR for assistance
with ﬂow cytometry and Veronica Macleod, Charlotte Smith, Sidra Ellis and Poppy
Begum for help with sample processing, RT-PCR and MLPA. UNC1999 and UNC2400
were kind gifts of the Structural Genomics Consortium, Oxford/Toronto, and
EPZ005687 was synthesised by Ludovic Drouin, Cancer Therapeutics Unit, The
Institute of Cancer Research, London.
REFERENCES
1 Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al. A novel
prognostic model in myeloma based on co-segregating adverse FISH lesions and
the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;
26: 349–355.
2 Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the
International Myeloma Working Group. Blood 2016; 127: 2955–2962.
3 Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al.
A validated gene expression model of high-risk multiple myeloma is deﬁned by
deregulated expression of genes mapping to chromosome 1. Blood 2007; 109:
2276–2284.
4 Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing
myeloma at last: deﬁning criteria and providing the evidence. Blood 2014; 124:
3043–3051.
5 Pawlyn C, Kaiser MF, Davies FE, Morgan GJ. Current and potential epigenetic
targets in multiple myeloma. Epigenomics 2014; 6: 215–228.
6 Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM et al. MMSET
deregulation affects cell cycle progression and adhesion regulons in t(4;14)
myeloma plasma cells. Haematologica 2009; 94: 78–86.
7 Mirabella F, Wu P, Wardell CP, Kaiser MF, Walker BA, Johnson DC et al. MMSET is
the key molecular target in t(4;14) myeloma. Blood Cancer J 2013; 3: e114.
8 Huang Z, Wu H, Chuai S, Xu F, Yan F, Englund N et al. NSD2 is recruited through its
PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Res 2013;
73: 6277–6288.
9 Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J et al. NSD2 links dimethy-
lation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 2011; 44:
609–620.
10 Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A et al. Aberrant
global methylation patterns affect the molecular pathogenesis and prognosis of
multiple myeloma. Blood 2011; 117: 553–562.
11 Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D
dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood
2005; 106: 296–303.
12 Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A et al. Proliferation
is a central independent prognostic factor and target for personalized and risk-
adapted treatment in multiple myeloma. Haematologica 2011; 96: 87–95.
13 Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular
classiﬁcation of multiple myeloma. Blood 2006; 108: 2020–2028.
14 Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life.
Nature 2011; 469: 343–349.
15 Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins. Nat
Struct Mol Biol 2013; 20: 1147–1155.
16 Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste
homolog 2 (EZH 2) is an oncogene that inﬂuences myeloma cell growth and the
mutant ras phenotype. Oncogene 2005; 24: 6269–6280.
17 van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C et al.
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.
Nat Genet 2009; 41: 521–523.
18 Hong S, Cho YW, Yu LR, Yu H, Veenstra TD, Ge K. Identiﬁcation of JmjC domain-
containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad
Sci USA 2007; 104: 18439–18444.
19 Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al. EZH2 is
required for germinal center formation and somatic EZH2 mutations promote
lymphoid transformation. Cancer Cell 2013; 23: 677–692.
20 Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis.
Leukemia 2014; 28: 44–49.
21 Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic
mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas
of germinal-center origin. Nat Genet 2010; 42: 181–185.
22 Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P et al. The
epigenetic modiﬁer EZH2 controls melanoma growth and metastasis through
silencing of distinct tumour suppressors. Nat Commun 2015; 6: 6051.
23 Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. EZH2 is a marker of
aggressive breast cancer and promotes neoplastic transformation of breast
epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606–11611.
24 Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al.
EZH2 expression is associated with high proliferation rate and aggressive tumor
subgroups in cutaneous melanoma and cancers of the endometrium, prostate,
and breast. J Clin Oncol 2006; 24: 268–273.
EZH2 as a therapeutic target in myeloma
C Pawlyn et al
9
Blood Cancer Journal
25 Papakonstantinou N, Ntoufa S, Chartomatsidou E, Kotta K, Agathangelidis A,
Giassafaki L et al. The histone methyltransferase EZH2 as a novel prosurvival
factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget 2016; 7:
35946–35959.
26 Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med 2016; 22: 128–134.
27 Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN et al. Strong expression of
EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma
independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma
2015; 56: 2895–2901.
28 Van der Meulen J, Speleman F, Van Vlierberghe P. The H3K27me3 demethylase
UTX in normal development and disease. Epigenetics 2014; 9: 658–668.
29 Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV et al. Synthetic
lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Nat Med 2015; 21: 231–238.
30 Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM et al.
Mutational spectrum, copy number changes, and outcome: results of a sequen-
cing study of patients with newly diagnosed myeloma. J Clin Oncol 2015; 33:
3911–3920.
31 Pawlyn C, Kaiser M, Heuck C, Melchor L, Wardell C, Murison A et al. The spectrum
and clinical impact of epigenetic modiﬁer mutations in myeloma. Clin Cancer Res
2016; 22: 5783–5794.
32 Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, Eriksson M et al.
Polycomb target genes are silenced in multiple myeloma. PLoS ONE 2010; 5:
e11483.
33 Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T
et al. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and repro-
grams the myeloma epigenome through global and focal changes in H3K36 and
H3K27 methylation. PLoS Genet 2014; 10: e1004566.
34 Hernando H, Gelato KA, Lesche R, Beckmann G, Koehr S, Otto S et al. EZH2
inhibition blocks multiple myeloma cell growth through upregulation of epithelial
tumor suppressor genes. Mol Cancer Ther 2016; 15: 287–298.
35 Agarwal P, Alzrigat M, Parraga AA, Enroth S, Singh U, Ungerstedt J et al. Genome-
wide proﬁling of histone H3 lysine 27 and lysine 4 trimethylation in multiple
myeloma reveals the importance of Polycomb gene targeting and highlights
EZH2 as a potential therapeutic target. Oncotarget 2016; 7: 6809–6823.
36 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al.
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for
newly diagnosed multiple myeloma patients destined for autologous stem-cell
transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012;
97: 442–450.
37 Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT et al. Effects
of induction and maintenance plus long-term bisphosphonates on bone disease
in patients with multiple myeloma: the Medical Research Council Myeloma
IX Trial. Blood 2012; 119: 5374–5383.
38 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G et al. Long-term
follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and
thalidomide treatment. Clin Cancer Res 2013; 19: 6030–6038.
39 Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority
of tandem autologous transplantation over standard therapy for previously
untreated multiple myeloma. Blood 1997; 89: 789–793.
40 Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al.
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl
J Med 2006; 354: 1021–1030.
41 Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al.
Incorporating bortezomib into upfront treatment for multiple myeloma: early
results of total therapy 3. Br J Haematol 2007; 138: 176–185.
42 van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y et al. Total
Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing
and premature discontinuation of VTD maintenance components, bortezomib,
thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010;
116: 1220–1227.
43 R Core Team. R: A Language and Environment for Statistical Computing. R Foundation
for Statistical Computing: Vienna, Austria, 2015. https://www.R-project.org/.
44 Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al.
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant
lymphoma cells. Nat Chem Biol 2012; 8: 890–896.
45 Kaiser MF, Walker BA, Hockley SL, Begum DB, Wardell CP, Gonzalez D et al. A TC
classiﬁcation-based predictor for multiple myeloma using multiplexed real-time
quantitative PCR. Leukemia 2013; 27: 1754–1757.
46 Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S et al. A molecular
diagnostic approach able to detect the recurrent genetic prognostic factors
typical of presenting myeloma. Genes Chromosomes Cancer 2015; 54: 91–98.
47 Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ et al. An orally
bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS
Chem Biol 2013; 8: 1324–1334.
48 Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG et al. Selective inhibition
of EZH2 and EZH1 enzymatic activity by a small molecule suppresses
MLL-rearranged leukemia. Blood 2015; 125: 346–357.
49 Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y et al.
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in
EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014; 13: 842–854.
50 Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell
cycle arrest. Nature 1994; 371: 257–261.
51 Xiao S, Li D, Zhu HQ, Song MG, Pan XR, Jia PM et al. RIG-G as a key mediator of the
antiproliferative activity of interferon-related pathways through enhancing p21
and p27 proteins. Proc Natl Acad Sci USA 2006; 103: 16448–16453.
52 Bradley WD, Arora S, Busby J, Balasubramanian S, Gehling VS, Nasveschuk CG
et al. EZH2 inhibitor efﬁcacy in non-Hodgkin's lymphoma does not require sup-
pression of H3K27 monomethylation. Chem Biol 2014; 21: 1463–1475.
53 Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT et al. EZH2 oncogenic activity in
castration-resistant prostate cancer cells is Polycomb-independent. Science 2012;
338: 1465–1469.
54 Benard A, Goossens-Beumer IJ, van Hoesel AQ, Horati H, Putter H, Zeestraten EC
et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone
modiﬁcation H3K27me3 in colorectal cancer. PLoS One 2014; 9: e108265.
55 Ribrag V, Soria J-C, Michot J-M, Schmitt A, Postel-Vinay S, Bijou F et al. Phase 1
study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2
(EZH2): preliminary safety and activity in relapsed or refractory non-Hodgkin
lymphoma (NHL) patients. Blood 2015; 126: 473.
56 Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev
Cancer 2009; 9: 400–414.
57 Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1
undergo normal development, but are defective in G1 checkpoint control. Cell
1995; 82: 675–684.
58 Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ.
Radiation-induced cell cycle arrest compromised by p21 deﬁciency. Nature 1995;
377: 552–557.
59 Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in
apoptosis. Mol Cancer Ther 2002; 1: 639–649.
60 Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A et al. Combined
epigenetic therapy with the histone methyltransferase EZH2 inhibitor
3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against
human AML cells. Blood 2009; 114: 2733–2743.
61 Bai J, Chen J, Ma M, Cai M, Xu F, Wang G et al. Inhibiting enhancer of zeste
homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by
activation of p21 and p16. DNA Cell Biol 2014; 33: 337–344.
62 Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CC et al. EZH2-dependent sup-
pression of a cellular senescence phenotype in melanoma cells by inhibition of
p21/CDKN1A expression. Mol Cancer Res 2011; 9: 418–429.
63 Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L et al. Mapping
of chromosome 1p deletions in myeloma identiﬁes FAM46C at 1p12 and CDKN2C
at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer
Res 2011; 17: 7776–7784.
64 Wang X, Zhu YB, Cui HP, Yu TT. Aberrant promoter methylation of p15 (INK(4)b)
and p16 (INK(4)a) genes may contribute to the pathogenesis of multiple
myeloma: a meta-analysis. Tumour Biol 2014; 35: 9035–9043.
65 Chen W, Wu Y, Zhu J, Liu J, Tan S, Xia C. Methylation of p16 and p15 genes in
multiple myeloma. Chin Med Sci J 2002; 17: 101–105.
66 Li J, Bi L, Lin Y, Lu Z, Hou G. Clinicopathological signiﬁcance and potential drug
target of p15INK4B in multiple myeloma. Drug Des Dev Ther 2014; 8: 2129–2136.
67 Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb
group protein EZH2 directly controls DNA methylation. Nature 2006; 439:
871–874.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)
EZH2 as a therapeutic target in myeloma
C Pawlyn et al
10
Blood Cancer Journal
